Speech prosody impairment predicts cognitive decline in Parkinson’s disease
Objective: We assessed whether baseline speech prosodic parameters, alone or in combination with other predominantly non-dopaminergic symptoms may predict global cognitive decline as measured by…Safety of nelotanserin in a randomized placebo-controlled phase 2 study
Objective: To explore the safety of nelotanserin in a phase 2 study in patients with nelotanserin. Background: Nelotanserin is a highly selective and poent inverse…Comparison of cognitive and neuropsychological manifestations in patients with progressive supranuclear palsy (Psp) and Parkinson’s disease
Objective: 1) To compare the cognitive and neuropsychological manifestations between the patients with PSP and PD. 2) To find out the severity of caregivers distress…Next-generation profiling to identify the molecular etiology of Parkinson’s disease dementia
Objective: To identify novel gene regulatory events associated with Parkinson's disease with dementia (PD-D). Background: PD-D is associated with the spread of degenerative pathology to…Depressive disorders in Parkinson’s disease and Alzheimer’s disease
Objective: Our primary aim was to study of the clinical characteristics of DD in patients with AD and PD. Background: The problem of a combination…Association between urine protein/creatinine ratio and cognitive dysfunction in Parkinson’s disease
Objective: We investigated the relationship between proteinuria and cognitive dysfunction in patients with Parkinson's disease. Background: Impaired renal function and proteinuria have been associated with…Effect of nelotanserin on objective sleep parameters in a phase 2 study in patients with insomnia
Objective: To understand the effects of nelotanserin on objective sleep parameters in a phase 2 study in patients with primary insomnia. Background: Nelotanserin is a…A novel phenotype of amyloid precursor protein (APP) mutation presenting with dementia, and symptoms of both progressive supranulcear palsy (PSP) and multisystem atrophy (MSA)
Objective: To describe the novel phenotype of a patient with an amyloid precursur protein (APP) mutation presenting with dementia and symptoms of both progressive supranulcear…Heart rate variability to differentiate dementia with Lewy bodies from Alzheimer’s disease in patients with mild cognitive impairment
Objective: We aimed to determine whether heart rate variability (HRV) can aid in the differentiation of DLB from AD at the MCI stage. Background: Mild…Genetic factors influencing frontostriatal dysfunction and the development of dementia in Parkinson’s disease
Objective: To investigate the role of APOE, MAPT, COMT, SNCA and GBA genes in both striatal dopaminergic denervation and the development of dementia in Parkinson's…
- « Previous Page
- 1
- …
- 28
- 29
- 30
- 31
- 32
- 33
- Next Page »